For instance, the North Central Cancer Treatment Group (NCCTG)/Alliance N0147 trial in 201420 demonstrated that KRAS sequence variation was more likely to occur proximally, a finding strengthened in a 2015 analysis of the same trial demonstrating that KRAS variants in tumors occurring distally were independently associated with mortality. This evidence concerns the gene KRAS and cancer.